SCHEMBL90592

SCHEMBL90592

CC(C)CC1(N)CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
TSHR P16473 2/20 0.41
ALOX15 P16050 1/20 0.41
HPGD P15428 1/20 0.39
CYP2D6 P10635 1/20 0.39
EPHX2 P34913 1/20 0.39
ATM Q13315 2/20 0.39
HTT P42858 2/20 0.39
OPRD1 P41143 1/20 0.38
OPRK1 P41145 1/20 0.38
NPC1 O15118 1/20 0.38
ALDH1A1 P00352 1/20 0.38
MAPT P10636 1/20 0.38
MAPK1 P28482 1/20 0.38
RAB9A P51151 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
DPP4 P27487 1/20 0.38
RECQL P46063 1/20 0.38
EPHX1 P07099 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL89880 0.91 USP2 (0.40) USP2SMN1; SMN2TSHRALOX15HPGD
SCHEMBL4278207 0.83 USP2 (0.46) USP2SMN1; SMN2TSHRALOX15HPGD
SCHEMBL1954007 0.83 USP2 (0.49) USP2SMN1; SMN2TSHRALOX15HPGD
SCHEMBL605572 0.83 USP2 (0.49) USP2SMN1; SMN2TSHRALOX15HPGD
SCHEMBL1586924 0.83 USP2 (0.49) USP2SMN1; SMN2TSHRALOX15HPGD
SCHEMBL19397229 0.82 USP2 (0.45) USP2SMN1; SMN2TSHRALOX15HPGD
SCHEMBL31726620 0.82 USP2 (0.45) USP2SMN1; SMN2TSHRALOX15HPGD
SCHEMBL8012970 0.81 USP2 (0.47) USP2SMN1; SMN2HPGDEPHX2OPRD1
SCHEMBL3187327 0.81 USP2 (0.47) USP2SMN1; SMN2TSHRALOX15HPGD
SCHEMBL89509 0.81 USP2 (0.44) USP2SMN1; SMN2TSHRALOX15HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129411-B2 Organic compounds NOVARTIS AG (CH) 2012-03-06 US disclosed
US-8129411-B2 Organic compounds NOVARTIS AG (CH) 2012-03-06 US disclosed
EP-2420491-A1 3 , 5-substitued piperidine compounds as renin inhibitors Novartis AG (CH) 2012-02-22 EP disclosed
US-20090192148-A1 Organic Compounds NOVARTIS AG (CH) 2009-07-30 US disclosed
US-20090192148-A1 Organic Compounds NOVARTIS AG (CH) 2009-07-30 US disclosed
WO-2007077005-A1 3 , 5-SUBSTITΓUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS NOVARTIS AG (CH) 2007-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192148-A1 Organic Compounds REN, ACE, AGTR1 USP2 3964/4885SMN1; SMN2 1867/4885TSHR 1095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.